These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 30031977

  • 1. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L, Huang X, Huang R, Gou S, Wang Z, Wang H.
    Eur J Med Chem; 2018 Aug 05; 156():666-679. PubMed ID: 30031977
    [Abstract] [Full Text] [Related]

  • 2. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
    Huang X, Wang M, Wang C, Hu W, You Q, Yang Y, Yu C, Liao Z, Gou S, Wang H.
    Bioorg Chem; 2019 Nov 05; 92():103236. PubMed ID: 31494328
    [Abstract] [Full Text] [Related]

  • 3. Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance.
    Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H.
    Bioorg Med Chem; 2017 Sep 01; 25(17):4686-4700. PubMed ID: 28728896
    [Abstract] [Full Text] [Related]

  • 4. Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action.
    Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H.
    Bioconjug Chem; 2016 Sep 21; 27(9):2132-48. PubMed ID: 27494235
    [Abstract] [Full Text] [Related]

  • 5. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F, Qin X, Xu G, Gou S, Jin X.
    Biochem Pharmacol; 2017 Jul 01; 135():50-68. PubMed ID: 28288821
    [Abstract] [Full Text] [Related]

  • 6. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.
    Wang M, Li G, Jiang G, Cai J, Liu Z, Huang R, Huang X, Wang H.
    J Med Chem; 2024 Apr 25; 67(8):6218-6237. PubMed ID: 38573870
    [Abstract] [Full Text] [Related]

  • 7. Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues.
    Huang X, Hua S, Huang R, Liu Z, Gou S, Wang Z, Liao Z, Wang H.
    Eur J Med Chem; 2018 Mar 25; 148():1-25. PubMed ID: 29448138
    [Abstract] [Full Text] [Related]

  • 8. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 9. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J, Pang Y, Sheng J, Wang Y, Chen J, Hu J, Huang L, Li X.
    Biochem Pharmacol; 2015 Sep 01; 97(1):51-61. PubMed ID: 26212540
    [Abstract] [Full Text] [Related]

  • 10. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
    Chen H, Wang X, Gou S.
    J Inorg Biochem; 2019 Apr 01; 193():133-142. PubMed ID: 30731264
    [Abstract] [Full Text] [Related]

  • 11. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
    Cai D, Qiu Z, Yao W, Liu Y, Huang H, Liao S, Luo Q, Xie L, Lin Z.
    Cancer Chemother Pharmacol; 2016 Jun 01; 77(6):1217-29. PubMed ID: 27107592
    [Abstract] [Full Text] [Related]

  • 12. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
    Liu Z, Wang M, Wang H, Fang L, Gou S.
    Eur J Med Chem; 2020 May 15; 194():112269. PubMed ID: 32248002
    [Abstract] [Full Text] [Related]

  • 13. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX, Wang ZF, Qin QP, Zou BQ, Liang H.
    Dalton Trans; 2020 Feb 07; 49(5):1613-1619. PubMed ID: 31942585
    [Abstract] [Full Text] [Related]

  • 14. Anticancer Platinum(IV) Prodrugs Containing Monoaminophosphonate Ester as a Targeting Group Inhibit Matrix Metalloproteinases and Reverse Multidrug Resistance.
    Huang X, Huang R, Gou S, Wang Z, Wang H.
    Bioconjug Chem; 2017 Apr 19; 28(4):1305-1323. PubMed ID: 28276682
    [Abstract] [Full Text] [Related]

  • 15. Pt(IV) Prodrug Photoactivation: A Promising Strategy for Cancer Therapy.
    Tang L, Luo Y, Luo W, Sun G, Jiang Y, Zhang Z, Yue X, Li S, Liang L, Liu W, Hu J.
    Curr Protein Pept Sci; 2024 Apr 19; 25(10):797-813. PubMed ID: 38919078
    [Abstract] [Full Text] [Related]

  • 16. Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance.
    Hu W, Fang L, Hua W, Gou S.
    J Inorg Biochem; 2017 Oct 19; 175():47-57. PubMed ID: 28700961
    [Abstract] [Full Text] [Related]

  • 17. Pt(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cells.
    Huang X, Huang R, Wang Z, Li L, Gou S, Liao Z, Wang H.
    Eur J Med Chem; 2018 Feb 25; 146():435-450. PubMed ID: 29407969
    [Abstract] [Full Text] [Related]

  • 18. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z, Xu Z, Zhu G.
    Angew Chem Int Ed Engl; 2016 Dec 12; 55(50):15564-15568. PubMed ID: 27736029
    [Abstract] [Full Text] [Related]

  • 19. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D, Tolan D, Andriollo E, Gandin V, Marzano C.
    Int J Mol Sci; 2018 Nov 27; 19(12):. PubMed ID: 30486477
    [Abstract] [Full Text] [Related]

  • 20. Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance.
    Chen F, Pei S, Wang X, Zhu Q, Gou S.
    Biochem Biophys Res Commun; 2020 Jan 15; 521(3):753-761. PubMed ID: 31703842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.